

Top Large Companies (more than 5,000 employees)

	Institution	Total No. R&D Employees	New R&D Employees	2007 Net Income (billion)	Significant Developments in the Past Year
1	Pioneer Hi-Bred	2,000	291	\$3.3 ¹	Completed FDA submissions for its Optimum GAT trait, which confers herbicide tolerance, in corn
2	AstraZeneca	13,000	*	\$29.5	Acquired MedImmune; 24 new molecules entered Phase 1 trials, 10 projects in Phase 3 trials
3	Genzyme	1,600	325	\$3.8	Acquired Bioenvision; successful Phase 2 trial of Alemtuzamab
4	Pfizer	14,300	1,200	\$8.1	Maraviroc approved by the FDA
5	Schering-Plough	4,435	*	\$15.2 ²	Acquired Organon BioSciences
6	Amgen	7,000	*	\$3.2	Submitted application for Nplate; 11 Phase 2 programs ongoing
7	Organon	2,965	*	\$15.2 ²	Acquired by Schering-Plough
8	Novartis	11,177	*	\$6.5	15 regulatory approvals in the US and Europe
9	Sigma-Aldrich	400	40	\$.311	Acquired Molecular Medicine BioServices and Epichem Group Ltd.
10	Wyeth	6,500	*	\$4.6	Achieved FDA approvals for Lybrel, Torisel, Xyntha and Pristiq

Top Small Companies (1,000 employees or less)

	Institution	Total No. R&D Employees	New R&D Employees	2007 Net Income (million)	Significant Developments in the Past Year
1	Tec Laboratories	11	1	*	Launched Staphaseptic, a topical antibiotic gel
2	Inspire Pharmaceuticals	65	3	none	Launched AzaSite; three product candidates in Phase 3 testing: denufosol, Prolacria, and epinastine nasal spray
3	Asterand	42	7	\$15.1	Awarded contract to assess the condition and value of the Department of Defense Armed Forces Institute of Pathology tissue repository
4	Millennium Pharmaceuticals	*	*	\$14.9	Filed a supplementary NDA and received priority review for Velcade
5	Infinity Pharmaceuticals	95	22	none	Advanced Retaspimycin into multiple clinical trials
6	Wyatt Technology	20	5	*	Held its 18th annual International Light Scattering Colloquium with a record number of attendees
7	Tengion	70	30	none	Started two Phase II trials on the Neo-Bladder Augment
8	Otsuka Maryland Medicinal Laboratories	43	1	\$1.4	Changed legal status from an LLC to a corporation.
9	Lexicon Pharmaceuticals	353	15	none	Launched an initiative to advance 10 drug candidates into human clinical trials by the end of 2010
10	TransForm Pharmaceuticals	84	11	*	Expanded collaborations with other Johnson & Johnson operating companies

¹ Gross income

² Schering-Plough and Organon BioSciences net income combined

* Company declined to provide information

Whether it's cookie Wednesdays at Vertex Pharmaceuticals or Friday "fermentation seminars" at Amgen, scientists appreciate feeling valued.